适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Antabio
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A PHASE-1, FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND FOOD EFFECT OF ORALLY ADMINISTERED VENT-03 IN HEALTHY VOLUNTEERSupus erythematosusMedDRA version: 21.1Level: LLTClassification code: 10025139Term: Lupus erythematosus systemic Class: 10028395CTIS2023-507504-31-00Ventus Therapeutics U.S. Inc.72
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
招募中
1 期
Phase 1 study in Staphylococcus aureus endocarditisInfectious S. aureus endocarditisMedDRA version: 20.1Level: LLTClassification code: 10041937Term: Staphylococcus aureus endocarditis Class: 10021881CTIS2023-505413-25-00Phaxiam Therapeutics12
进行中（未招募）
1 期
Effects of NT-0796 in Healthy Volunteers and Patients with Parkinson’s DiseaseMedDRA version: 21.1Level: LLTClassification code: 10013113Term: Disease Parkinson's Class: 10029205Parkinson's DiseaseCTIS2023-503203-29-00odthera Limited14
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290